FDA Approved: AVODART — Supplemental Application (Waylis Therapeutics LLC)

View source ↗

Summary

FDA approves a supplemental application for AVODART (dutasteride) submitted by Waylis Therapeutics LLC under NDA 021319.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Avodart (dutasteride)

Snippet

SUPPL AP for AVODART (DUTASTERIDE)